ADVANCEMENTS IN CRISPR-CAS9 GENE EDITING: IMPLICATIONS FOR HUMAN THERAPEUTICS

Abstract

CRISPR-Cas9 technology has revolutionized the field of molecular genetics by enabling precise, efficient, and cost-effective genome editing across a wide range of organisms. Originally derived from the bacterial adaptive immune system, this versatile system allows targeted manipulation of DNA sequences, opening new avenues for therapeutic applications in genetic disorders, oncology, and regenerative medicine.This study provides a comprehensive examination of advancements in CRISPR-Cas9, incorporating high-fidelity Cas9 variants, next-generation editing systems such as Cas12, Cas13, and prime editors, as well as improvements in delivery mechanisms including viral vectors, lipid nanoparticles, and electroporation. A structured methodology was employed to evaluate editing efficiency, off-target risk, and delivery performance across model organisms, tissue types, and clinical applications.Results indicate a high degree of editing accuracy with minimal off-target effects when using engineered Cas9 variants. Base and prime editing platforms demonstrated superior single-nucleotide correction potential, while lipid-based delivery systems outperformed viral methods in safety and efficiency. In therapeutic contexts, CRISPR demonstrated significant efficacy in correcting mutations in sickle cell anemia and cystic fibrosis, and in enhancing CAR-T cell function in hematologic malignancies. Safety profiles across trials showed a low incidence of severe adverse events, supporting the clinical viability of the technology.The findings underscore the transformative potential of CRISPR-Cas9 in modern medicine, while also emphasizing the need for continued attention to ethical, regulatory, and long-term safety concerns. With advancements in precision tools, delivery strategies, and interdisciplinary integration, CRISPR is poised to transition from experimental innovation to a cornerstone of personalized therapeutics.